A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07316062

Acronym

MAP

Enrollment

3000

Registered

2026-01-05

Start date

2026-04-29

Completion date

2029-04-30

Last updated

2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small-Cell Lung

Keywords

NSCLC, chart review

Brief summary

This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.

Detailed description

The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Stage I-III at initial NSCLC diagnosis * Aged ≥18 years at first diagnosis of NSCLC * Timeframe of NSCLC diagnosis: For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027

Exclusion criteria

* NSCLC is not the primary cancer diagnosis * Patients with a recent history of other tumor or concurrent other tumor * Patients participating in interventional clinical trials at time of initial diagnosis * Patients with positive pregnancy status at the time of diagnosis

Design outcomes

Primary

Measure	Time frame	Description
Treatment Patterns	Up to 50 months	Proportion of patients with different treatment regimens
Proportion of unresected patients in SI/II/III	Up to 50 months	Proportion of patients who are unresected among SI/II/III NSCLC patients enrolled, respectively
CRT rate in USIII	Up to 50 months	Proportion of patients who have CRT regimen among unresected SIII patients enrolled

Secondary

Measure	Time frame	Description
Treatment Duration	Up to 50 months	TKI treatment duration and discontinuation reason in EGFRm patients * Duration of treatment * Treatment discontinuation (time to discontinuation, and reason for discontinuation)
Patterns of recurrence	Up to 50 months	Type of recurrence following initial treatment regimen (Loco-regional recurrence, distant recurrence, other)
Guideline adoption rate	Up to 50 months	Resected EGFRm Stage IB-III * Proportion of patients received guideline recommended TKI adjuvant regimen among a. resected EGFRm Stage IB-III patients; b. patients with TKI adjuvant therapy Unresected Stage III * Proportion of patients received guideline recommended systemic IO and TKI regimens among patients who received CRT

Countries

China

Contacts

CONTACTAstraZeneca Clinical Study Information Center

information.center@astrazeneca.com1-877-240-9479

Outcome results